Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C. Berger NA, et al. Among authors: liaudet l. Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26. Br J Pharmacol. 2018. PMID: 28213892 Free PMC article. Review.
Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis.
Mukhopadhyay P, Rajesh M, Cao Z, Horváth B, Park O, Wang H, Erdelyi K, Holovac E, Wang Y, Liaudet L, Hamdaoui N, Lafdil F, Haskó G, Szabo C, Boulares AH, Gao B, Pacher P. Mukhopadhyay P, et al. Among authors: liaudet l. Hepatology. 2014 May;59(5):1998-2009. doi: 10.1002/hep.26763. Epub 2014 Apr 1. Hepatology. 2014. PMID: 24089324 Free PMC article.
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P, Horváth B, Rajesh M, Varga ZV, Gariani K, Ryu D, Cao Z, Holovac E, Park O, Zhou Z, Xu MJ, Wang W, Godlewski G, Paloczi J, Nemeth BT, Persidsky Y, Liaudet L, Haskó G, Bai P, Boulares AH, Auwerx J, Gao B, Pacher P. Mukhopadhyay P, et al. Among authors: liaudet l. J Hepatol. 2017 Mar;66(3):589-600. doi: 10.1016/j.jhep.2016.10.023. Epub 2016 Oct 29. J Hepatol. 2017. PMID: 27984176
The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Ahmad A, Vieira JC, de Mello AH, de Lima TM, Ariga SK, Barbeiro DF, Barbeiro HV, Szczesny B, Törö G, Druzhyna N, Randi EB, Marcatti M, Toliver-Kinsky T, Kiss A, Liaudet L, Salomao R, Soriano FG, Szabo C. Ahmad A, et al. Among authors: liaudet l. Pharmacol Res. 2019 Jul;145:104263. doi: 10.1016/j.phrs.2019.104263. Epub 2019 May 6. Pharmacol Res. 2019. PMID: 31071432 Free PMC article.
235 results